1 week Ago By ABMN Staff
Vaxcyte, Inc. ( NASDAQ:PCVX – Get Free Report ) has received an average rating of “Buy” from the seven brokerages that are presently covering the stock, MarketBeat reports. Seven analysts have rated the stock with a buy rating.
The average 12 month target price among brokers that have covered the stock in the last year is $131.83. Several research analysts have issued reports on the stock.
Leerink Partners raised their price target on shares of Vaxcyte from $106.00 to $153.00 and gave the stock an “outperform” rating in a report on Tuesday, September 3rd.
Jefferies Financial Group lifted their target price on shares of Vaxcyte from $108.00 to $129.00 and gave the stock a “buy” rating in a research note on Tuesday, September 3rd.
Needham & Company LLC upped their price target on shares of Vaxcyte from $95.00 to $140.00 and gave the company a “buy” rating in a research report on Tuesday, September 3rd.
Bank of America lifted their price objective on Vaxcyte from $101.00 to $140.00 and gave the stock a “buy” rating in a research report on Wednesday.
Finally, BTIG Research boosted their price objective on Vaxcyte from $98.00 to $160.00 and gave the company a “buy” rating in a research note on Tuesday, September 3rd.
View Our Latest Analysis on Vaxcyte Insider Buying and Selling at Vaxcyte Hedge Funds Weigh In On Vaxcyte Hedge funds have recently added to or reduced their stakes in the stock. Goldman Sachs Group Inc. boosted its holdings in Vaxcyte by 12.
1% during the 4th quarter. Goldman Sachs Group Inc. now owns 481,119 shares of the company’s stock worth $30,214,000 after acquiring an additional 52,005 shares during the last quarter.
Natixis Advisors L.P. bought a new position in shares of Vaxcyte during the fourth quarter valued at about $881,000.
Vestal Point Capital LP purchased a new position in Vaxcyte during the fourth quarter worth about $32,970,000. Harbor Capital Advisors Inc. grew its position in Vaxcyte by 392.
4% in the 2nd quarter. Harbor Capital Advisors Inc. now owns 40,342 shares of the company’s stock worth $3,046,000 after purchasing an additional 32,149 shares in the last quarter.
Finally, TD Asset Management Inc increased its stake in Vaxcyte by 10.5% in the 4th quarter. TD Asset Management Inc now owns 167,036 shares of the company’s stock valued at $10,490,000 after buying an additional 15,890 shares during the last quarter.
Institutional investors and hedge funds own 96.78% of the company’s stock. Vaxcyte Stock Down 0.
5 % NASDAQ PCVX opened at $111.58 on Tuesday. The company has a market capitalization of $12.
14 billion, a price-to-earnings ratio of -26.07 and a beta of 0.97.
Vaxcyte has a twelve month low of $44.20 and a twelve month high of $119.27.
The stock has a fifty day simple moving average of $81.80 and a 200 day simple moving average of $73.53.
Vaxcyte ( NASDAQ:PCVX – Get Free Report ) last issued its quarterly earnings results on Tuesday, August 6th. The company reported ($1.10) earnings per share for the quarter, missing the consensus estimate of ($0.
98) by ($0.12). During the same quarter in the prior year, the business earned ($0.
70) earnings per share. Research analysts expect that Vaxcyte will post -4.33 earnings per share for the current fiscal year.
Vaxcyte Company Profile ( Get Free Report Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.
See Also Receive News & Ratings for Vaxcyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vaxcyte and related companies with MarketBeat.com's FREE daily email newsletter ..
